Every medication has side effects, and semaglutide is no exception. For most patients, the side effects are manageable — primarily gastrointestinal and concentrated in the early weeks of treatment. For some, they are significant enough to require dose adjustments. For a small minority, they are serious enough to contraindicate the medication entirely.
This guide explains what side effects are most common, why they happen, how they are managed, and what warning signs require immediate physician contact. If you are considering a medical weight loss program with semaglutide, understanding the side effect profile is an essential part of making an informed decision.
The Most Common Side Effects of Semaglutide
The most common side effects of semaglutide are gastrointestinal. In the STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021), nausea was reported by approximately 44% of participants at some point during the 68-week trial — making it by far the most frequently reported adverse effect. Most of these episodes were mild to moderate in severity, and the majority resolved by week 20 as participants adapted to the medication.
The most commonly reported GI side effects include:
- Nausea — the most common; typically peaks during dose escalation and resolves over time
- Vomiting — less common than nausea; often associated with eating too quickly or too much during early treatment
- Diarrhea — reported by approximately 30% of participants in STEP 1 at some point; usually mild
- Constipation— also common; related to semaglutide's gastric emptying effects
- Fatigue during dose escalation — some patients report increased tiredness during the first few weeks or immediately after dose increases; typically transient
Why Nausea Happens — and When It Goes Away
Nausea from semaglutide has a specific mechanism. The medication slows gastric emptying — food moves more slowly from the stomach into the intestines. When food remains in the stomach longer than normal, particularly after larger meals or high-fat meals, nausea is the result.
This is why semaglutide nausea is most pronounced in the first 4–8 weeks and during each dose increase: the body has not yet adapted to the altered gastric motility at the new dose level. As adaptation occurs, nausea typically diminishes significantly at each dose tier — and most patients find that by the time they reach the therapeutic dose, the initial nausea has largely resolved.
Practical approaches that reduce nausea during the adjustment period:
- Eat smaller meals — avoid eating until uncomfortably full
- Avoid high-fat or fried foods, which slow gastric emptying further
- Stay well hydrated, particularly between meals
- Avoid lying down immediately after eating
- Eat slowly and stop as soon as fullness begins
The dose titration schedule is the most important tool for managing nausea. Starting at the lowest dose (0.25 mg weekly) and increasing gradually allows the body to adapt before the dose rises further. Patients who escalate too quickly experience more severe and prolonged nausea. This is why physician-guided titration — not a preset app schedule — matters.
Less Common Side Effects
Beyond the core GI side effects, some patients experience:
- Hair thinning (telogen effluvium) — this is not a drug-specific side effect of semaglutide itself. It is a response to rapid weight loss and significant caloric restriction. When the body experiences rapid physiological change, hair follicles can enter a resting phase simultaneously, causing noticeable shedding 2–3 months later. Adequate protein intake reduces this risk. Hair typically regrows after weight stabilizes.
- Headache — reported by some patients, particularly during dose escalation; usually mild and transient
- Dizziness — most often related to reduced caloric intake or dehydration; ensure adequate fluid and electrolyte intake
- Low blood sugar (hypoglycemia) — semaglutide alone has a low risk of causing hypoglycemia in non-diabetic patients because its insulin-stimulating effect is glucose-dependent. The risk increases significantly if semaglutide is combined with insulin or other diabetes medications that independently lower blood sugar. Patients on diabetes medications require closer monitoring and possible dose adjustments.
Serious but Rare Risks to Know
The following risks are uncommon but important for any patient considering semaglutide to understand:
- Pancreatitis — acute pancreatitis has been reported in patients taking GLP-1 receptor agonists, though a direct causal relationship has not been definitively established. The risk is considered low, but semaglutide should be discontinued if severe or persistent abdominal pain develops (particularly pain that radiates to the back). Patients with a history of pancreatitis are typically not candidates for semaglutide.
- Thyroid tumors — in animal studies, GLP-1 receptor agonists including semaglutide caused thyroid C-cell tumors at doses significantly above therapeutic human doses. The clinical significance of this finding in humans is uncertain — it has not been confirmed in human studies. However, semaglutide carries a contraindication for patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2). This is a screening question at every Vitality consultation.
- Gallbladder disease — rapid weight loss of any cause is associated with increased risk of gallstone formation. Semaglutide-induced weight loss shares this general risk. Patients with a history of gallbladder disease should discuss this with Dr. Jaqua before starting.
These risks are presented to inform — not alarm. The benefit-risk profile of semaglutide in appropriately selected patients, under physician supervision, is strongly favorable. The key is appropriate patient selection and ongoing monitoring.
How Vitality Manages Dosing to Reduce Side Effects
Vitality's approach to semaglutide dosing is physician-guided from the first prescription. There is no preset escalation schedule that applies to every patient uniformly.
Treatment begins at the lowest effective dose. Dr. Jaqua reviews how each patient is tolerating the current dose before authorizing a dose increase. If a patient is experiencing significant side effects, the dose is held rather than advanced. If a patient tolerates a dose well and has significant room for improvement, the timeline may be adjusted appropriately.
Regular check-ins are built into the program — not optional. This is how early warning signs are caught before they become serious issues, and how the protocol is continuously optimized for each individual patient. The goal is the best tolerated, most effective dose for that specific person — not the maximum labeled dose.
When to Contact Your Doctor
Contact Dr. Jaqua or seek medical attention immediately if you experience any of the following:
- Severe or persistent abdominal pain — particularly pain in the upper abdomen that radiates to the back; this can indicate pancreatitis
- A lump or swelling in the neck, difficulty swallowing, or persistent hoarseness — potential thyroid warning signs; stop the medication and contact your physician
- Vision changes — some patients with diabetes on GLP-1 medications have reported early diabetic retinopathy changes; report any new or worsening vision symptoms
- Severe vomiting that prevents hydration — dehydration is a real risk; do not wait to contact your physician if you cannot keep fluids down
- Signs of an allergic reaction — rash, itching, swelling, or difficulty breathing after injection
Side effects are manageable when the medication is prescribed and monitored by a physician. If you are ready to explore whether semaglutide is right for you, learn more about Vitality's medical weight loss program or book a free consultation to review your health history and labs.
Frequently Asked Questions
How long do semaglutide side effects last?
Gastrointestinal side effects — particularly nausea — are most prominent during the first 4–8 weeks of treatment and during dose escalation periods. For most patients, nausea improves significantly or resolves entirely as the body adapts to each dose level. In the STEP 1 trial, nausea was reported by approximately 44% of participants at some point, but the majority of episodes were mild to moderate and resolved without requiring discontinuation. Patients who continue through the initial adjustment period typically find subsequent dose increases cause less discomfort than the first.
Does tirzepatide have the same side effects?
Tirzepatide shares a similar side effect profile to semaglutide because both are GLP-1 receptor agonists. Nausea, vomiting, diarrhea, and constipation are the most common side effects of both medications. The dual GIP/GLP-1 mechanism of tirzepatide does not significantly change the GI side effect pattern. Patients who do not tolerate semaglutide well do not necessarily tolerate tirzepatide better — or worse. Side effect experience is individual, and Dr. Jaqua monitors both medications with the same titration protocols.
Can I take antinausea medication with semaglutide?
Over-the-counter antinausea medications (such as dimenhydrinate or ginger supplements) are sometimes used during the initial adjustment period. However, persistent or severe nausea is a signal that dose escalation has moved too quickly — a dose hold or reduction is often more appropriate than masking the side effect. Any antinausea medication use should be discussed with Dr. Jaqua, as some formulations can interact with semaglutide's gastric emptying effects.
Should I stop semaglutide if I feel sick?
Mild nausea during the first few weeks of treatment, or immediately following a dose increase, is expected and does not require stopping. However, you should contact your physician if you experience: severe or persistent abdominal pain (possible pancreatitis warning), vomiting that prevents you from staying hydrated, severe diarrhea lasting more than a few days, or any of the red-flag symptoms listed in the 'When to Contact Your Doctor' section of this article. A temporary dose hold or reduction is often more appropriate than full discontinuation — that decision should be made with physician input.
References
- Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine. 2021;384:989–1002. (STEP 1 trial)
- FDA Prescribing Information — Wegovy (semaglutide) injection. U.S. Food & Drug Administration. 2021.